BR112013028095A2 - inibidores de csf-1r para o tratamento de tumores cerebrais - Google Patents

inibidores de csf-1r para o tratamento de tumores cerebrais

Info

Publication number
BR112013028095A2
BR112013028095A2 BR112013028095A BR112013028095A BR112013028095A2 BR 112013028095 A2 BR112013028095 A2 BR 112013028095A2 BR 112013028095 A BR112013028095 A BR 112013028095A BR 112013028095 A BR112013028095 A BR 112013028095A BR 112013028095 A2 BR112013028095 A2 BR 112013028095A2
Authority
BR
Brazil
Prior art keywords
treatment
compound
csf
formula
inhibitors
Prior art date
Application number
BR112013028095A
Other languages
English (en)
Other versions
BR112013028095B1 (pt
Inventor
Dylan Daniel
James Sutton
Johanna Joyce
Original Assignee
Novartis Ag
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Sloan Kettering Inst Cancer filed Critical Novartis Ag
Publication of BR112013028095A2 publication Critical patent/BR112013028095A2/pt
Publication of BR112013028095B1 publication Critical patent/BR112013028095B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

resumo patente de invenção: "inibidores de csf-1r para o tratamento de tumores cerebrais". a presente invenção refere-se a um composto de fórmula i: (i) em que r1 é uma alquil pirazol ou uma alquil carboxamida e r2 é uma hidroxicicloalquila; ou um sal farmaceuticamente aceitável do mesmo, e composições que contêm estes compostos para uso no tratamento de um tumor cerebral, particularmente glioblastoma. a invenção proporciona um tratamento eficaz de um tumor cerebral e pode ser usada através de administração oral de um composto de fórmula i, conforme ainda descrito aqui. a invenção também proporciona um método para tratar um indivíduo que tem um tumor cerebral, tal como glioblastoma, em que o método compreende administração, ao indivíduo, de uma quantidade eficaz de um composto de fórmula i. assinaturas gênicas correlacionadas ao tratamento com sucesso usando estes métodos são também descritas.
BR112013028095-6A 2011-05-05 2012-05-04 Uso de inibidores de csf-1r para o tratamento de tumores cerebrais BR112013028095B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161482723P 2011-05-05 2011-05-05
US61/482,723 2011-05-05
US201261624861P 2012-04-16 2012-04-16
US61/624,861 2012-04-16
PCT/US2012/036589 WO2012151523A1 (en) 2011-05-05 2012-05-04 Csf-1r inhibitors for treatment of brain tumors

Publications (2)

Publication Number Publication Date
BR112013028095A2 true BR112013028095A2 (pt) 2016-12-27
BR112013028095B1 BR112013028095B1 (pt) 2020-03-03

Family

ID=46062775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013028095-6A BR112013028095B1 (pt) 2011-05-05 2012-05-04 Uso de inibidores de csf-1r para o tratamento de tumores cerebrais

Country Status (19)

Country Link
US (3) US20140065141A1 (pt)
EP (1) EP2704713B1 (pt)
JP (1) JP6046702B2 (pt)
KR (1) KR101938431B1 (pt)
CN (1) CN103501785B (pt)
BR (1) BR112013028095B1 (pt)
CA (1) CA2834696C (pt)
CY (1) CY1119642T1 (pt)
DK (1) DK2704713T3 (pt)
EA (1) EA023999B1 (pt)
ES (1) ES2622527T3 (pt)
HR (1) HRP20170593T1 (pt)
HU (1) HUE032754T2 (pt)
LT (1) LT2704713T (pt)
MX (1) MX347616B (pt)
PL (1) PL2704713T3 (pt)
PT (1) PT2704713T (pt)
SI (1) SI2704713T1 (pt)
WO (1) WO2012151523A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014147631A1 (en) * 2013-03-22 2014-09-25 Natco Pharma Limited Formulation comprising gefitinib as oral suspension
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
WO2016189045A1 (en) * 2015-05-27 2016-12-01 Ucb Biopharma Sprl Method for the treatment of neurological disease
CN108367070B (zh) * 2015-11-04 2022-10-28 杜克大学 免疫毒素与检查点抑制剂的组合治疗
EP3526217B1 (en) * 2016-10-14 2023-04-19 Novartis AG Crystalline forms of 4-(2-((1r,2r)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-n-methylpicolinamide
WO2018069893A1 (en) * 2016-10-14 2018-04-19 Novartis Ag Methods for treating ocular disease using inhibitors of csf-1r
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
AU2018275891A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods related to toxicity associated with cell therapy
BR112019025403A2 (pt) 2017-06-02 2020-08-18 Juno Therapeutics Inc artigos de fabricação e métodos para tratamento usando terapia celular adotiva
JP2020526194A (ja) 2017-06-29 2020-08-31 ジュノー セラピューティクス インコーポレイテッド 免疫療法薬と関連する毒性を評価するためのマウスモデル
MA50057A (fr) 2017-09-01 2020-07-08 Juno Therapeutics Inc Expression génique et évaluation d'un risque de développement d'une toxicité suite à une thérapie cellulaire
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
EP3836951A1 (en) 2018-08-13 2021-06-23 Signablok, Inc. Peptides and compositions for targeted treatment and imaging
BR112021010120A2 (pt) 2018-11-30 2021-08-31 Juno Therapeutics, Inc. Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
SG11202105502RA (en) 2018-11-30 2021-06-29 Juno Therapeutics Inc Methods for treatment using adoptive cell therapy
CN110468210A (zh) * 2019-09-12 2019-11-19 暨南大学 Cdc45作为胶质母细胞瘤标志物及其作为治疗靶点的应用
BR112022010310A2 (pt) 2019-12-06 2022-08-16 Juno Therapeutics Inc Métodos relacionados com a toxicidade e resposta associada com terapia celular para tratamento de malignidades de célula b
MX2023003182A (es) * 2020-09-21 2023-04-12 Hutchison Medipharma Ltd Compuestos heteroaromaticos y usos de los mismos.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100721656B1 (ko) 2005-11-01 2007-05-23 주식회사 엘지화학 유기 전기 소자
PT2010496E (pt) * 2006-04-14 2010-10-13 Astrazeneca Ab 4-anilinoquinolina-3-carboxamidas como inibidores de csf-1r cinase
TW200813039A (en) * 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
CN101432281B (zh) * 2006-04-19 2013-08-28 诺瓦提斯公司 6-0-取代的苯并*唑和苯并噻唑化合物以及抑制csf-1r信号传导的方法
US8859602B2 (en) 2006-04-20 2014-10-14 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
KR20100017866A (ko) * 2007-05-21 2010-02-16 노파르티스 아게 Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법

Also Published As

Publication number Publication date
JP6046702B2 (ja) 2016-12-21
HUE032754T2 (en) 2017-10-30
CY1119642T1 (el) 2018-04-04
MX347616B (es) 2017-05-04
AU2012250574B2 (en) 2016-07-07
CA2834696C (en) 2019-07-23
AU2012250574A1 (en) 2013-11-28
LT2704713T (lt) 2017-04-25
CN103501785B (zh) 2016-10-26
PL2704713T3 (pl) 2017-08-31
US20140065141A1 (en) 2014-03-06
WO2012151523A1 (en) 2012-11-08
DK2704713T3 (en) 2017-04-24
US20150306085A1 (en) 2015-10-29
MX2013012939A (es) 2014-02-27
EA023999B1 (ru) 2016-08-31
KR101938431B1 (ko) 2019-01-14
US20190030013A1 (en) 2019-01-31
HRP20170593T1 (hr) 2017-07-14
AU2012250574A8 (en) 2016-07-28
KR20140029475A (ko) 2014-03-10
EP2704713B1 (en) 2017-01-18
US10537561B2 (en) 2020-01-21
PT2704713T (pt) 2017-04-24
CA2834696A1 (en) 2012-11-08
EP2704713A1 (en) 2014-03-12
EA201391629A1 (ru) 2016-01-29
BR112013028095B1 (pt) 2020-03-03
ES2622527T3 (es) 2017-07-06
JP2014513136A (ja) 2014-05-29
CN103501785A (zh) 2014-01-08
SI2704713T1 (sl) 2017-05-31

Similar Documents

Publication Publication Date Title
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
NZ726366A (en) Syk inhibitors
PH12016501204A1 (en) Syk inhibitors
MX349159B (es) Derivados deuterados de ivacaftor.
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
NZ708593A (en) Novel pyrazole derivative
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201490396A1 (ru) Ингибиторы репликации вирусов гриппа
BR112014029016A2 (pt) derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral
WO2015157559A3 (en) 10&#39;,11&#39;-modified saxitoxins useful for the treatment of pain
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
BR112013025634A2 (pt) inibidores de hsp90
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.
EA201590697A1 (ru) Производные кетамина
BR112014001369A2 (pt) derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
MX2015008187A (es) Inhibidores de alk deuterados.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/05/2012, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 11A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2721 DE 28-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.